Astellas Reports Record Q1 FY2026 Revenue of ¥640.9B, Driven by Strategic Brands Growth and Raises Full-Year Outlook
Astellas Pharma Inc. (TYO: 4503) announced first-quarter fiscal year 2026 financial results featuring revenue of...
Astellas Pharma
Astellas Pharma Submits BLA to China NMPA for PADCEV-Keytruda Combination in Muscle-Invasive Bladder Cancer, Showing 60% Reduction in Recurrence Risk for Cisplatin-Ineligible Patients
Astellas Pharma Inc. (TYO: 4503) announced that China’s National Medical Products Administration (NMPA) has accepted...
Astellas Pharma Unveils CSP2026 Strategic Plan Targeting Pipeline-Driven Growth and Strategic Brand Expansion
Astellas Pharma Inc. (TYO: 4503) has unveiled its Corporate Strategic Plan 2026 (CSP2026), a comprehensive...
Astellas and MSD’s PADCEV-Keytruda Combination Receives Positive CHMP Opinion for Muscle-Invasive Bladder Cancer in EU
Astellas Pharma Inc. (TYO: 4503) announced that the Committee for Medicinal Products for Human Use...
Astellas Reports Strong FY2025 Results with 12% Revenue Growth Driven by Oncology Portfolio Expansion
Astellas Pharma Inc. (TYO: 4503) reported FY2025 financial results showing JPY 2,139.2 billion (USD 13.9...
FDA Grants Priority Review to Merck, Astellas, and Pfizer’s sBLA for Padcev-Pembrolizumab Combo in Perioperative Muscle-Invasive Bladder Cancer
Merck & Co. (MSD, NYSE: MRK), Astellas Pharma (TYO: 4503), and Pfizer Inc. (NYSE: PFE)...
Astellas’ XOSPATA Fails Phase III Primary Endpoint in Frontline AML – FLT3 Inhibitor Misses OS Benefit vs. Midostaurin
Astellas Pharma Inc. (TYO: 4503) and the HOVON Foundation announced that the Phase III HOVON...
Astellas and Vir Biotechnology Partner on $1.7B+ PRO-XTEN TCE Deal – VIR-5500 Targets PSMA in Prostate Cancer
Astellas Pharma Inc. (TYO: 4503) and Vir Biotechnology, Inc. (NASDAQ: VIR) announced a global strategic collaboration to...
Astellas’ VENTANA CLDN18 Assay Wins NMPA Approval as First Companion Diagnostic for VYLOY
Astellas Pharma Inc. (TYO: 4503) announced that its VENTANA CLDN18 (43-14A) Assay has received approval...
Pfizer-Astellas’ PADCEV Wins FDA Approval for Perioperative Bladder Cancer
Pfizer Inc. (NYSE: PFE) and Astellas Pharma Inc. (TYO: 4503) announced that the U.S. Food...
Astellas Pharma Posts 10% Revenue Rise and 54% Core Operating‑Profit Surge in H1 FY2025
Astellas Pharma Inc. (TYO: 4503) released its consolidated six‑month results for fiscal year 2025 (1 Apr 2025 – 30 Sep 2025). The...
Astellas Establishes First China Innovation R&D Center in Beijing BioPark
Astellas Pharma (TYO: 4503) announced on October 27, 2025, the establishment of its first China...
Astellas China Secures GBA Approval for First‑in‑Class Fezolinetant (VEOZA)
Astellas (TYO: 4503) China announced that its global first‑in‑class, non‑hormonal, selective neurokinin‑3 (NK3) receptor antagonist...
PADCEV Yields 60 % EFS Reduction in MIBC – Astellas‑Pfizer EV‑303 Study
Astellas (TSE: 4503) and Pfizer (NYSE: PFE) announced that their pivotal Phase III EV‑303 (KEYNOTE‑905) trial...
Pfizer and Astellas’ Xtandi Shows Positive Results in Phase III EMBARK Study for Prostate Cancer
Partners Pfizer (NYSE: PFE) and Astellas Pharma Inc. (TYO: 4503) announced positive topline results from...
Astellas Pharma’s Vyloy Gains First Prescriptions Across China for Gastric Cancer
Japan-based Astellas Pharma Inc. (TYO: 4503) announced that the first prescriptions for Vyloy (zolbetuximab) in...
MRI and Astellas Alliance to Boost Japanese Drug Discovery Startups
Japan-based Mitsubishi Research Institute, Inc. (MRI) and Astellas Pharma Inc. (TYO: 4503) announced the signing...
Astellas Pharma Licenses Evopoint’s CLDN18.2 ADC for Global Development
Japan-based Astellas Pharma Inc. (TYO: 4503) has entered into a licensing agreement with China-headquartered Evopoint...
Chromatin Bioscience Collaborates with Astellas Pharma to Design Cell-Selective Synthetic Promoters
UK-headquartered Chromatin Bioscience has entered into a collaboration with Japan-based Astellas Pharma Inc. (TYO: 4503)...
Astellas Pharma Partners with Shanghai Pharma on Zolbetuximab Commercialization
Japan-based Astellas Pharma Inc. (TYO: 4503) announced a strategic partnership with Shanghai Pharmaceuticals (SPH; SHA:...